We are live on ! Find out more
CLYM

Climb Bio
CLYM

22 hedge funds and large institutions have $46.8M invested in Climb Bio in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more funds holding

Funds holding: 19 → 22 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

0.87% less ownership

Funds ownership: 62.86% → 61.99% (-0.87%)

3% less capital invested

Capital invested by funds: $48.4M → $46.8M (-$1.59M)

Holders
22
Holders Change
+3
Holders Change %
+15.79%
% of All Funds
0.34%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
6
Reduced
6
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$416K
2
TSS
Two Sigma Securities
New York
+$43.4K
3
Osaic Holdings
Osaic Holdings
Arizona
+$25.3K
4
SCM
Silverarc Capital Management
Massachusetts
+$24.7K
5
TRCT
Tower Research Capital (TRC)
New York
+$4.53K

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$228K
2
Morgan Stanley
Morgan Stanley
New York
-$184K
3
Millennium Management
Millennium Management
New York
-$8.17K
4
CPIG
Chicago Partners Investment Group
Illinois
-$5.92K
5
BlackRock
BlackRock
New York
-$2.46K

CLYM Hedge Fund Activity: Q2 2023 in Review

22 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q2 2023, worth a combined $46.8M — down 3.3% from $48.4M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CLYM positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 6 trimmed.

The largest buyer was Driehaus Capital Management, adding an estimated $416K. The largest seller was BML Capital Management, cutting an estimated $228K.

  • 22 institutional investors held Climb Bio (CLYM) as of Q2 2023, up from 19 in Q1 2023.
  • Funds reported $46.8M of Climb Bio stock for Q2 2023, down 3.3% quarter-over-quarter.
  • 3 funds opened new Climb Bio positions in Q2 2023 and 0 closed out, a net change of +3 holders.
  • The largest Climb Bio buyer in Q2 2023 was Driehaus Capital Management, an estimated $416K added.
  • The largest Climb Bio seller in Q2 2023 was BML Capital Management, an estimated $228K sold.

Based on aggregated 13F filings for Q2 2023.